Marshall Wace, LLP Arrowhead Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $5.07 Million - $6.98 Million	-193,393 Reduced 64.24%	107,648 $2.89 Million
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $7.57 Million - $12.5 Million	301,041 New	301,041 $10.7 Million
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $5.08 Million - $9.25 Million	-182,799 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $2.68 Million - $4.73 Million	-67,581 Reduced 26.99%	182,799 $8.41 Million
Q2 2021 Aug 13, 2021	BUY	$62.15 - $90.32 $15.6 Million - $22.6 Million	250,380 New	250,380 $20.7 Million

Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $17.7 Million - $26 Million	-287,817 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$43.82 - $85.37 $12.6 Million - $24.6 Million	287,817 New	287,817 $22.1 Million

296

88.5M

905K

387K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.71B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.